All In Biotech

Drug Trial Radar · NCT06579755

A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled (Older Adults, Aged >60 to 79 Years) and Open-Label (Adults, Aged 45 to 60 Years), Multicenter Trial to Investigate the Safety and Immunogenicity of a Dengue Tetravalent Vaccine (TDV) Administered Subcutaneously to Adults and Older Adults With or Without Comorbidities in Endemic Areas for Dengue

Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 800 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

800

Actual

Start

Jan 20, 2026

Primary completion

Apr 14, 2027

Study completion Apr 14, 2027

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Aug 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 45 years, up to 79 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Dengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever. Researchers have seen that dengue fever now also happens more often in elderly persons. The main aim of this study is to learn more about the side effects of TDV in adult (45 - 60 years) and elderly (60 - 79 years) persons and about TDV's ability to create an immune response in adult and elderly persons. Another aim is to learn about the side effects of TDV in adult and elderly persons in endemic countries who have one or more additional medical conditions (called comorbidities) such as diabetes mellitus, hypertension or a chronic kidney condition. In this study, participants will receive 2 vaccinations with TDV (the second 3 months after the first). During the study, participants will visit their study clinic 5 times.

Conditions

  • Dengue Fever

Interventions

  • TDVBiological

    TDV SC injection.

  • PlaceboOther

    Placebo SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Solicited Local (Injection Site) Adverse Events (AEs) Within 7 Days Post Vaccination at Day 1Time frame: Within 7 days post-vaccination at Day 1
  2. Number of Participants with Solicited Local (Injection Site) Adverse Events (AEs) Within 7 Days Post Vaccination at Day 90Time frame: Within 7 days post-vaccination at Day 90
  3. Number of Participants with Solicited Systemic AEs Within 14 Days Post Vaccination at Day 1Time frame: Within 14 days post-vaccination at Day 1
  4. Number of Participants with Solicited Systemic AEs Within 14 Days Post Vaccination at Day 90Time frame: Within 14 days post-vaccination at Day 90
  5. Percentage of Participants with Solicited Local (Injection Site) AEs by Severity Within 7 Days Post Vaccination at Day 1Time frame: Within 7 days post-vaccination at Day 1
  6. Percentage of Participants with Solicited Local (Injection Site) AEs by Severity Within 7 Days Post Vaccination at Day 90Time frame: Within 7 days post-vaccination at Day 90
  7. Percentage of Participants with Solicited Systemic AEs by Severity Within 14 Days Post Vaccination at Day 1Time frame: Within 14 days post-vaccination at Day 1
  8. Percentage of Participants with Solicited Systemic AEs by Severity Within 14 Days Post Vaccination at Day 90Time frame: Within 14 days post-vaccination at Day 90
  9. Percentage of Participants with Any Unsolicited AEs Within 28 Days Post Vaccination at Day 1Time frame: Within 28 days post-vaccination at Day 1
  10. Percentage of Participants with Any Unsolicited AEs Within 28 Days Post Vaccination at Day 90Time frame: Within 28 days post-vaccination at Day 90
  11. Percentage of Participants with a Serious Adverse Event (SAE)Time frame: From first vaccination on Day 1 through the end of trial (up to Day 270)
  12. Geometric Mean Titers (GMTs) of Neutralizing Antibodies by Microneutralization Test (MNT) for Each of the 4 Dengue Virus Serotypes at Day 120Time frame: At Day 120

Locations

7 sites in 4 countries. Site status is shown where the registry gives one.

  • Fundacion Huesped - PPDS

    Buenos Aires, Argentina

  • Associacao Obras Sociais Irma Dulce Hospital Santo Antonio

    Salvador, Estado de Bahia, Brazil

  • Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS

    São José do Rio Preto, São Paulo, Brazil

  • Singapore General Hospital (SGH)

    Singapore, Singapore

  • Tan Tock Seng Hospital

    Singapore, Singapore

  • Ramathibodi Hospital

    Ratchathewi, Bangkok, Thailand

  • Hospital for Tropical Diseases

    Ratchathewi, Krung Thep Maha Nakhon-Bangkok, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.